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all 3 studies were analysed using latent growth models to generate intercepts and 
slopes of change across trials for each patient, irrespective of treatment. Slopes 
of change were correlated to examine how closely DLQI changes mirrored UAS7 
changes. Results: Results indicated that both measures showed large improve-
ments over the course of the trials: UAS7 and DLQI scores were high at the start 
of the study reflecting moderate-severe CSU/CIU (UAS7) and a very large effect on 
patient’s life (DLQI). Correlations between changes in DLQI and changes in UAS7 by 
study end were 0.88, 0.85, and 0.88, indicating high correspondence between the two 
measures. ConClusions: These results suggest that collecting DLQI information 
in-clinic can provide an excellent indication of the weekly UAS7 score, and is more 
efficient for clinical practice routine in assessing CSU/CIU patients.
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objeCtives: Some psoriasis patients also have psoriatic arthritis (PsA), which 
increases disease burden and further reduces quality-of-life (QoL). Our objective 
was to compare QoL of subjects with both psoriasis and PsA to those with psoriasis 
alone, and to evaluate improvement on etanercept (ETN) therapy in specific coun-
tries of Central and Eastern Europe, Latin America, and Asia where data are lim-
ited. Methods: Patients with moderate/severe psoriasis were randomized to 50mg 
ETN QW (once weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg 
QW (weeks 13-24). The following post-hoc assessments were included: EuroQoL-5D 
(EQ-5D); Dermatology Quality of Life Index (DLQI); Functional Assessment of Chronic 
Illness Therapy (FACIT)-Fatigue; Hospital Anxiety and Depression Scale (HADS); 
Medical Outcomes Study (MOS)-Sleep; and Work Productivity and Activity Impairment 
(WPAI). Subjects with and without PsA were pooled across ETN groups for compari-
sons of changes in scores from baseline to week 24, which were based on independent 
sample t-tests. Results: Of 171 subjects analysed, 64 (37.4%) had PsA. Baseline demo-
graphic characteristics and QoL measures were similar in PsA and psoriasis-alone 
groups. EQ-5D scores improved significantly over time with ETN treatment in both 
subjects with and without PsA (P< 0.0001) with similar adjusted mean improvement 
in both groups after 24 weeks (0.2 vs 0.2; P= 0.6202). Improvement in EQ-5D greater 
than MID (change ≥ 0.05) at week 24 was observed in a greater proportion of PsA than 
psoriasis-alone subjects (74.6% vs 63.8%; P= 0.174). Significant improvements from 
baseline in both PsA and psoriasis-alone groups were also observed after 24 weeks in 
DLQI (both P< 0.0001), FACIT (both P< 0.01) and HADS anxiety (both P< 0.0001) scores. 
Improvements of other patient-reported outcomes were also observed at weeks 24 in 
both disease subgroups. ConClusions: ETN in both dose regimens provided signifi-
cant improvement in QoL measures in subjects with moderate-to-severe psoriasis, 
regardless of the presence of PsA.
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objeCtives: To assess the impact of etanercept (ETN) on quality-of-life (QoL) through 
24 weeks in patients with moderate/severe psoriasis in specific countries of Central 
and Eastern Europe, Latin America, and Asia where data are limited. Methods: 
Patients with moderate/severe psoriasis were randomized to 50mg ETN QW (once 
weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg QW (weeks 
13-24). Patients completed the Dermatology Life Quality Index (DLQI) EuroQoL 5D (EQ-
5D), FACT-Fatigue, HADS Anxiety Score, Psoriasis Subject Satisfaction Questionnaire, 
and Work Productivity Activity Impairment (WPAI) at baseline and subsequent vis-
its. Results: Of 171 patients analysed, 85 were randomised to ETN BIW and 86 to ETN 
50 QW. Baseline DLQI scores were 14.8 in both treatment groups suggesting severe 
QoL impairment. Significant improvements in DLQI from baseline were observed 
at weeks 12 and 24 in both groups (all p< 0.0001); mean improvement at week 12 for 
ETN BIW was greater than for ETN QW (10.8 vs 8.4, p= 0.001), but was similar between 
groups at week 24 (11.0 vs 9.5, p= 0.063). EQ-5D utility was significantly improved 
from baseline in both groups at weeks 12 and 24 (all p< 0.0001), with mean improve-
ment significantly greater for the higher dose at both time-points (week 12: 0.3 vs. 
0.2, p= 0.029; week 24: 0.3 vs. 0.2, p= 0.027). Mean EQ-5D improvement at week 24 
was greater than MID (change ≥ 0.05) in a significantly greater proportion of patients 
receiving BIW than QW (77.1% vs 58.8%; p= 0.013). Improvements of other patient-
reported outcomes from baseline were observed at weeks 12 and 24 in both treat-
ment groups. ConClusions: At baseline, patients had severely impaired QoL, and 
improvement in QoL was achieved with both ETN regimens. Improvements observed 
with ETN BIW were significantly greater than with ETN QW for both DLQI and EQ-5D 
utility at week 12, but only for EQ-5D at week 24.
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used, thus confirming external validity. The mean score calculated from the ABS 
is 48.17±18.36. The score increases with the severity of the AD. A statistically sig-
nificant difference is observed between the 3 severity-groups, i.e. mild, moderate 
and severe, with scores of 30.63, 42.55 and 62.62 respectively. ConClusions: The 
internal and external validity of our Q were confirmed. ABS is correlated with the 
severity of AD. Hence, we have a short, easy-to-use, validated tool for assessing the 
burden imposed by atopy on families. Following cultural and linguistic validation, 
the ABS is now available in US English, Spanish, German and Italian.
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objeCtives: The notion of individual burden, associated with the disease, has 
been introduced recently to determine the “disability” caused by the pathology in 
the broadest sense of the word (psychological-social-economic-physical). The aim 
of our study is to develop a specific questionnaire for assessing the burden on fami-
lies of children with HI. Methods: A “Hemangioma Family Burden” questionnaire 
(HFB) consisting of 22 items, The score increases with the heaviness of the burden. It 
was distributed accompanied by 2 validated QoL questionnaires (SF12 and PGWBI) 
to obtain internal and external validation Results: A total of 58 evaluable Q were 
returned. One parent from each family described how they perceived the effects of 
the disease, which led to the creation of 6 severity groups, paired together for size 
reasons: “not-very-far-reaching” and “somew-hat-far-reaching”; “quite-far-reaching” 
and “far-reaching”; “very far-reaching” and “extremely far-reaching”. Internal validity 
was measured by Cronbach’s alpha, which is equal to 0.95, reflecting a good homoge-
neity of the 22 Q items. The mean scores of the physical and mental components are 
54.93±5.12 and 40.49±11.28 respectively. Hence, the HFB score is correlated with these 
2 components, thus confirming external validity. The mean score calculated from the 
HFB is 23.42±19.93. The score increases with the “severity score” of the parents. In 
fact, a statistically significant difference is observed between the 3 severity groups: 
5.28±6.8 for those reporting the smallest extent to 41.0±18.71 for those reporting the 
greatest extent, and 27.7±16.96 for a moderate extent. This confirms the sensitivity of 
the HFB ConClusions: During the evaluation, internal and external validity were 
confirmed. The HFB is correlated with the extent felt by parents, a feeling deemed 
relevant because it is often the cause of consultation and demand for treatment. 
We now have an easy-to-use, validated IH tool for assessing the disability caused. 
Following cultural and linguistic validation, the HFB is now available in US English, 
Spanish, German and Italian.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show improve-
ments in health-related quality of life (HRQoL). Glaucoma is a chronic disease 
with high importance for patient HRQoL. The objective of this study was to review, 
analyze, and understand trends in the PRO instruments used in patients with 
Glaucoma. Methods: A systematic literature search for Glaucoma trials with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study size, interventions, year, 
PRO instrument and results for PROs. Analysis for conducted to identify trends 
in commonly used PRO instruments and categorize results as positive, neutral or 
negative. Results: A total of 31 studies with a total of 9819 patients were identi-
fied. In these studies there were eleven different PROs instruments were identified 
that were Glaucoma health perception index, Glaucoma quality of life question-
naire (Glau-QoL), Glaucoma utility index, Impact of vision impairment, Low vision 
quality of life questionnaire, National eye institute visual function index-19 items, 
National eye institute visual function index-51 items, Nursing home vision quality 
of life questionnaire, Quality of life and visual function questionnaire, Vision core 
module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). ConClusions: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to generate 
evidence to show which therapies improve patient QoL.
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objeCtives: The UAS7 is a patient-reported measure of urticaria symptoms. Daily 
pruritus scores and number of hives are summed over 7 days for a weekly score. The 
DLQI was developed as a brief (10-item) patient-reported measure with one-week 
recall for routine clinical use to assess the psychosocial effects of skin disease. The 
objective of this analysis was to examine changes in the UAS7 with those of the 
DLQI to see if the DLQI could be used in a clinic visit in lieu of collecting one week 
of UAS7 diary data. Methods: Data come from three pivotal, phase 3 clinical tri-
als investigating the effects of omalizumab for patients with refractory CSU/CIU 
(publication available elsewhere). DLQI data were collected at baseline and weeks 
4, 12, 24, and 40 (ASTERIA I and GLACIAL), and baseline and weeks 4, 12, and 28 
(ASTERIA II). UAS7 score was reported at baseline and every four weeks but data 
from the same weeks as the DLQI were used for these analyses. Pooled data from 
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objeCtives: To assess the yearly frequency of ranibizumab injections for the treat-
ment of wet Age-Related Macular Degeneration (wAMD) in two large Canadian 
public drug plans: Ontario Public Drug Program (OPDP) and Régie de l’assurance-
maladie du Québec (RAMQ). Methods: Pharmastat database (IMS Health Canada 
Inc.) was used to assess the mean annual number of ranibizumab injections for 
wAMD patients covered by the OPDP or RAMQ drug plans (1 injection was defined 
as 1 claim). Only wAMD treatment-naïve patients were included and the index 
date was defined as the date of the first ranibizumab claim. The analysis looked 
at monthly data from March 2008 to November 2012 for OPDP patients and from 
January 2008 to May 2012 for RAMQ patients and tracked the mean number of 
claims during the patient’s first, second, third and fourth year of ranibizumab 
therapy. Results: For the OPDP, the mean number of ranibizumab injections was 
6.0, 5.4, 5.5 and 5.6 for year 1 (N= 26,606), year 2 (N= 19,466), year 3 (N= 12,708), and 
year 4 (N= 6,681), respectively. For the RAMQ, the mean number of injections was 
5.4, 4.7, 5.2 and 5.7 for year 1 (N= 3,457), year 2 (N= 2,185), year 3 (N= 1,178), and year 
4 (N= 349), respectively. ConClusions: These results suggest that many Ontario 
and Quebec retina specialists and ophthalmologists do not treat monthly but rather 
adopt an individualized ranibizumab treatment regimen to manage their patients’ 
wAMD. In addition, these results provide information on the real-world utilization of 
ranibizumab in wAMD for up to four years of treatment. The analyses, conclusions, 
opinions and statements expressed are those of Novartis Pharmaceuticals Canada 
Inc., and not those of IMS Health Canada Inc.
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objeCtives: To date, there has not been extensive study on the economics or estab-
lished treatment guidelines in patients with non-infectious posterior uveitis (NIPU). 
Current treatment is mostly topical/systemic/injection corticosteroids, though treat-
ment is associated with significant side effects. We undertook a secondary research 
analysis of MarketScan claims data to better understand the patient journey and the 
current treatment standard of care for NIPU patients. Methods: We analyzed the 
MarketScan dataset to identify NIPU patients from a defined list of ICD-9 codes. We 
then identified patients with 30 months of continuous enrollment data, 6 months 
prior and 24 months post initial diagnosis. Patients were assessed for number of 
office visits/procedures, number of diagnostic tests, number of inpatient stays, and 
number and frequency of drug treatment (corticosteroids, corticosteroid injections, 
immunomodulators, and biologics). Results: Of the 56 million lives in the claims 
dataset, 34,827 had an ICD-9 code consistent with NIPU. Of these unique patients, 
33,386 were analyzed. 78.8% of patients came from the commercial dataset, 59% 
of patients were female, and the average age at diagnosis was 51.5 years. Prior to 
diagnosis, 5,775 patients were treated for NIPU at an average cost of $185.43 per 
patient (58.0% topical/systemic corticosteroids, 22.7% corticosteroid injections, 
15.7% immunomodulators, 3.7% biologics). In the 24 months post-diagnosis, the 
number of treated patients increased to 11,570 patients at an average cost of $249.01 
per patient (45.7% topical/systemic corticosteroids, 37.4% corticosteroid injections, 
16.4% immunomodulators, 3.2% biologics). Examining each six-month period post-
diagnosis, the number of treated patients decreased, but the share of treatments 
remained the same. ConClusions: Patients with NIPU are engaging the health 
care system and being treated for NIPU at least six months prior to an official 
diagnosis. Efforts should be made to better identify patients with NIPU to ensure 
proper diagnosis and treatment.
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objeCtives: Waiting time for medical consultation is an important quality indi-
cator of health systems. International studies have shown that there is consider-
able variation of waiting time between countries. It may also vary within countries 
depending on the degree of emergency, indication, and way of reimbursement. Our 
objective was to assess practice organization and waiting times in German derma-
tological practices. Methods: A one page questionnaire was sent to be returned 
anonymously by fax to 2,644 German office base dermatologists randomly selected. 
Included were items on organization of practice, region and specific average waiting 
times for selected diagnoses. The postal codes obtained from the practices were 
mapped to the 17 German regions of physicians association of statutory health 
insurance. Results: Data sets were obtained from 681 practices. A total of 4.3% of 
practices rarely or never gave fixed appointments, 36.3% only gave fixed appoint-
ments. The percentage of treatment at fixed appointments varied by regions from 
71.1% in Bremen and Brandenburg to 90.0% in Hessen. Moreover, private practices 
not being associated with the statutory health system showed a higher rate of timed 
appointments with 94.8% compared to 83.0%. Average waiting time in practices 
treating also patients with statutory health insurance is 5 weeks and thus 4 times 
higher compared to waiting time in practices treating private insured patients only 
(1.2 weeks). There was large variation in waiting time for the first appointment 
between different indications. Patients with acute eczema or pigmented lesions 
specific for melanoma were given appointments after 1.7 or 1.2 weeks, respec-
tively; for skin cancer screening, patients had to wait for 5.7 weeks on average. 
There was only small geographic variation regarding this pattern. ConClusions: 
Patients with risky and acute indications are treated with low waiting times whereas 
patients with less threating skin diseases have to wait longer for appointments at 
dermatological offices.
objeCtives: To assess the quality of life (QoL) of patients with an exudative Age-
Related Macular Degeneration (AMD) treated by intravitreal Anti-VEGF (vascular 
endothelial growth factor) and determine its drivers in a real-life setting. Methods: 
A self-reported survey was carried out among AMD patients belonging to 2 French 
associations. Only patients with exudative AMD and under active intravitreal anti-
VEGF treatment over the last 6 months were included. Data on demographics, 
disease parameters, past and ongoing treatments were collected. One validated 
vision-specific QoL instrument was also considered: the NEI-VFQ-25. Patients were 
stratified into four groups of visual acuity (VA). A multivariate model was performed 
to identify the QoL drivers. Results: Out of the 1,888 questionnaires mailed 32.4% 
were returned and 24.7% fulfilled the inclusions criteria and were fully completed 
for analyses. Patients’ mean age was 78.0 years (SD 7.6). A total of 70.5% were 
women. A total of 60.4% had bilateral disease. The mean duration of symptomatic 
exudative AMD was respectively of 7.2 (SD 5) and 2.3 years (SD 3) for the first and the 
second eye. Most of anti-VEGF treated eyes (n= 641) were treated for more than 1 year 
(77.4%). The mean annual number of anti-VEGF injections was 4.7 (SD 2.7). The mean 
NEI-VFQ-25 global score was 53.4 (SD 21.5). A decrease of this score was positively 
correlated to VA decrease (0.63;p< .0001). This correlation was observed for 11 sub-
scales out of 12. The main risk factor associated to the lower Qol score was the worst 
VA category, with an odds ratio of 5.2 (CI95%[2.6-10.4];p< .0001). ConClusions: In 
a real-life survey of patients treated and followed for exudative AMD, VA decrease 
was the strongest factor linked to QoL worsening. Other factors such as the number 
of Anti-VEGF injections were not correlated to QoL in this study. Then, preservation 
of useful VA still remains a major concern to improve patients’ QoL.
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objeCtives: This abstract describes attempts to evaluate the burden of dry eye dis-
ease with regards to vision-related quality of life (QoL) and the causal link to general 
health related quality of life. Recent increased awareness of dry eye disease (DED) 
by both health care professional and patients has been accompanied by improved 
recognition that it is a chronic disorder often requiring long-term treatment and 
management. DED, frequently associated with symptoms of discomfort and visual 
disturbance, also impairs general health status and general quality of life, including 
aspects of physical, social, and psychological functioning. This abstract summarizes 
the available research on the burden of DED and the impact on QoL. Methods: 
The research included systematic literature search on clinical relevant DED litera-
ture based on HTA relevant requirements, in order to identify potential differences 
within DED. Correlations with socio- demographic characteristics, clinical param-
eters, and psychological status were evaluated. Results: A relative small amount 
of data supporting the effectiveness of DED treatments as assessed by QoL measures 
exists (such as DEQLQ, IDEEL etc.). Dry eye treatments have been associated with 
improvements in symptoms measured by OSDI (Ocular Surface Disease Index), and 
in ophthalmology-disease-specific measurement of QoL, and with enhancement of 
patients’ ratings regarding their ability to perform activities of daily life. Significant 
correlations were found between symptoms score and QoL scores and patient anxi-
ety, especially depression levels which correlates to general health. ConClusions: 
Vision-related QoL in dry eye patients was correlated with general health status, 
especially with anxiety and depression. DED has further implication on general 
public health and deserves an increased attention and resources.
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objeCtives: To examine the experience of physicians who treat patients with 
pemphigus vulgaris (PV) in Canada as well as the utilization and access of the drug 
rituximab (Rtx). Methods: An online questionnaire was created in SurveyMonkey® 
to collect data from participants based on a convenience sample size of 10 English-
speaking dermatologists. Consent was implied once the dermatologist completed the 
questionnaire. Non-identifying information for both dermatologists and PV patients 
was collected. Results: The 10 participating dermatologists have been treating PV 
patients an average of 20.9 ± 10.7 (5 – 45) years in which 28.8 ± 58.3 (0 – 200) was the 
mean number in their practice. Experience with Rtx is based on an average of 4.1 ± 
3.8 (0 – 10) years and 13.1 ± 29.2 (0 – 100) PV patients treated with Rtx. All participants 
answered that “failure of conventional therapy for at least six months” was the pri-
mary reason for using Rtx and that azathioprine, intravenous immunoglobulin and 
mycophenolate mofetil were the most popular treatments used to treat PV patients 
prior to Rtx. On average, it takes 3.2 ± 2.2 (0 – 6) months for a remission to be induced 
after Rtx treatment and 90% of the dermatologists were concerned that infections 
would be an adverse event. Lastly, 6.3 ± 12.3 (0 – 40) was the mean number of Rtx drug 
reimbursement letters that the dermatologists had written on behalf of PV patients 
in which 1.9 ± 2.5 (0 – 6) letters were successful in securing Rtx drug reimburse-
ments. ConClusions: A recent survey of 10 Canadian dermatologists experienced 
with treating PV patients found that Rtx utilization is still new, disease remission is 
achieved within a short period of time, and the drug reimbursement process remains 
a barrier based on the low number of letters written by the dermatologists.
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